Health Canada says it’s working with producers to make diabetes medication, together with Ozempic, extra obtainable throughout a worldwide scarcity fuelled by excessive demand that’s anticipated to final into the brand new 12 months.
It says Novo Nordisk, which markets Ozempic, is anticipating a scarcity in Canada of the 0.25 mg, 0.5 mg and 1 mg injection pens till early 2024.
Eli Lilly, which markets Trulicity and Mounjaro, can also be anticipating decrease provides of each medication all through early 2024.
Health Canada says efforts are being made to extend manufacturing capability however it’ll take time to construct up provide ranges.
In the meantime, it’s recommending that prescribers don’t begin new sufferers on the medication, until there are not any appropriate alternate options and there’s a scientific cause to take action.
The regulator says the medication, usually used for weight reduction, must be conserved for individuals who haven’t any different remedy selections as each drug firms are asking pharmacists to restrict refill prescriptions to a 30-day provide.
